Connexin 43 hemichannels and related diseases
Antibody Therapeutics · 05.10.2024 · 7 (4) · 361-369
DOI: 10.1093/abt/tbae024 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Antibody Therapeutics, online erschienen am 11.11.2024. Verfasst von Yanfeng Zhang und 2 weiteren Autor:innen. Beteiligte Einrichtung: AlaMab Therapeutics Inc, 302 Carnegie Center Dr Suite 100, Princeton, NJ 08540, United States. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 127 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDDK NIH HHS, Welch Foundation, NIH.
Abstract (Originalsprache)
Connexin 43 (Cx43) protein forms hemichannels (connexons) and gap junctions, with hemichannels consisting of six Cx43 molecules and gap junctions formed by two hemichannels. While gap junctions are prevalent in organs like the heart and liver, hemichannels are found in specific cell types, such as astrocytes and osteocytes. They allow the passage of small molecules (<1.5 kDa) between the cytoplasm and extracellular matrix. Cx43 hemichannels have emerged as potential therapeutic targets in various diseases, including central nervous system disorders, bone-related diseases, diabetic complications, wound healing, and cancers. Aberrant hemichannel opening can worsen conditions by releasing inflammatory elements, such as causing gliosis in neuronal cells. Conversely, functional hemichannels may inhibit cancer cell growth and metastasis. Recent studies are revealing new mechanisms of Cx43 hemichannels, broadening their therapeutic applications and highlighting the importance of regulating their activity for improved disease outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- AlaMab Therapeutics Inc, 302 Carnegie Center Dr Suite 100, Princeton, NJ 08540, United States.
- Department of Biochemistry and Structural Biology, University of Texas Health Science Center, San Antonio, TX 78229, United States.
ORCID-Profile: Jean X Jiang
Förderung
- NIDDK NIH HHS
- Welch Foundation
- NIH
- AlaMab Therapeutics
Zitieren
APA
Zhang, Y., Acosta, F. M., & Jiang, J. X. (2024). Connexin 43 hemichannels and related diseases. Antibody Therapeutics, 7(4), 361-369. https://doi.org/10.1093/abt/tbae024
Vancouver
Zhang Y, Acosta FM, Jiang JX. Connexin 43 hemichannels and related diseases. Antibody Therapeutics. 2024;7(4):361-369. doi:10.1093/abt/tbae024
BibTeX
@article{Zhang2024,
author = {Zhang, Yanfeng and Acosta, Francisca M and Jiang, Jean X},
title = {Connexin 43 hemichannels and related diseases},
journal = {Antibody Therapeutics},
year = {2024},
volume = {7},
number = {4},
pages = {361--369},
doi = {10.1093/abt/tbae024}
}
EUVIMED